Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MSB-3
- Development stage
- Preclinical
- Lead developer
- ASAKE Biotechnology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MSB-3 is a small molecule therapeutic candidate currently in preclinical development by ASAKE Biotechnology for the treatment of Type 1 Diabetes (T1D). The compound is designed to intervene in the disease process by modulating pathways within pancreatic beta cells that govern insulin production and programmed cell death (apoptosis). By protecting beta cells from destruction and enhancing their secretory capacity, MSB-3 represents a potential disease-modifying approach to maintaining glycemic control in T1D patients.
Beyond the preview
Go deeper on MSB-3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MSB-3.